Skip to main content

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Aplicación de la tecnología de secuenciación masiva para optimizar el coste-efectividad del tratamiento de la hepatitis C (VHC) en la era de los inhibidores de acción directa (DAAs).

IP: Juan Ignacio Esteban Mur
Collaborators: Lluís Viladomiu Catà, Lluis Castells Fusté, Josep Quer Sivila, Cristina Dopazo Taboada
Funding agency: Instituto de Salud Carlos III
Funding: 192692.5
Reference: PI13/00456
Duration: 01/01/2014 - 31/01/2017

Estudio de quasiespecies de los virus de la hepatits B y C (VHB y VHC) y de polimorfismos genómicos asociados a respuesta al tratamiento antiviral por pirosecuenciación

IP: Juan Ignacio Esteban Mur
Collaborators: -
Funding agency: CENTRO PARA EL DESARROLLO TÉCNICO INDUSTRIAL (CDTI
Funding: 875000
Reference: CDTI-2010-01
Duration: 01/03/2010 - 30/04/2013

Expansión/restauración funcional de células CD4 NS3 específicas autólogas en la prevención de la recurrencia VHC post-trasplante hepático: optimización del proceso para uso clínico

IP: Juan Ignacio Esteban Mur
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté, Silvia Sauleda Oliveras, Isabel Campos Varela, Marta Bes Maijo, Maria Madeleine Piron
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI10/01505
Duration: 01/01/2011 - 30/06/2014

Unitat de Recerca en Malalties Hepatobiliars

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Lluis Castells Fusté, Silvia Sauleda Oliveras, Lluís Palenzuela Díaz, Maria Buti Ferret, Josep Quer Sivila, Unitat de Recerca en Malalties Hepatobiliars, Juan Ignacio Esteban Mur, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 54080
Reference: 2009 SGR 383
Duration: 01/01/2010 - 30/04/2014

Related news

The results, published in The Lancet and Nature Medicine, provide new evidence to improve the diagnosis of metabolic dysfunction-associated steatotic liver disease and reduce the need for liver biopsies.

The CHANCE study analyzes the outcomes of nearly 1,000 patients at 63 liver transplant centers and identifies which patients with the most severe forms of the disease may benefit from transplantation.

The grants support projects led by Drs. María José Buzón, María Buti, Elena Élez, and Maria Vieito.

Related professionals

Cristina Morales Sala

Cristina Morales Sala

Research assistant
Multidisciplinary Nursing Research Group
Read more
Neus Boto Ruiz

Neus Boto Ruiz

Research assistant
Transfusional Medicine
Read more
Judit Domingo Prim

Judit Domingo Prim

Gestió i Administració
Business Development Unit
Directorate of Innovation and Business Development
Read more
Leila Alvarez Ferrfiro

Leila Alvarez Ferrfiro

Research assistant
Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.